How to manage a CRO: an insider's playbook for biotech founders

Managing a contract research organization (CRO) well means keeping the decisions the regulations will not let you outsource: selecting a qualified vendor, defining the work in writing, reviewing data as it arrives, and documenting that you did so. Under 21 CFR 312.52 a sponsor may transfer obligations to a CRO, but it stays accountable for the study, and FDA inspectors look for evidence of that oversight.

What can a CRO take off your plate, and what can it never take?

FDA defines a CRO as an independent contractor that assumes one or more of the sponsor's obligations, such as protocol design, selection or monitoring of investigations, evaluation of reports, and preparation of FDA submissions [1]. In practice this spans clinical operations, GLP toxicology, bioanalysis, and manufacturing. The sponsor's own duties under 21 CFR 312.50 include selecting qualified investigators, ensuring proper monitoring, keeping the study on protocol, and promptly reporting significant new risks [2].

ICH E6(R3) says the same thing in Good Clinical Practice (GCP) language. Principle 10 states that a sponsor may transfer activities but retains overall responsibility, and Annex 1 places ultimate responsibility for participant protection and data reliability with the sponsor, including for work the CRO subcontracts [4]. FDA issued E6(R3) as final guidance in September 2025 [5].

How do I select a CRO I can actually oversee?

Selection is itself a regulated act. 21 CFR 312.53 requires a sponsor to select investigators qualified by training and experience, and a monitor qualified the same way [6]. E6(R3) makes the sponsor responsible for assessing each provider's suitability, with access to its SOPs and performance metrics [4]. My request for proposals asks for the SOP index, audit history, staff turnover, and recent inspection outcomes.

I run a capability audit before award. For nonclinical work I confirm Good Laboratory Practice (GLP) status directly: 21 CFR 58.35 requires an independent quality assurance unit that inspects each study and signs a statement in the final report [7]. For clinical work I ask for the named project manager and monitors and how many sites each carries. Reference checks with sponsors of your own size tell you more than brand.

What belongs in the contract before any work starts?

Start with the written transfer of obligations. FDA's inspection program tells investigators to obtain every written agreement, including any separate transfer of regulatory obligations document, and to check whether the sponsor reported the transfer to FDA as 21 CFR 312.23 requires [8]. The Form FDA 1571 instructions require, in Field 16, the CRO's name and address, the study, and a list of the obligations transferred [9]. I draft that list myself.

Define deliverables, acceptance criteria, and the change-order process before the first invoice. E6(R3) states that agreements should secure the sponsor's right to monitor and audit, with direct access to source records and facilities, including those of service providers [4]. Put data ownership in writing: data, metadata, and audit trails belong to the sponsor and are delivered on request within stated days.

Records clauses matter. For GLP studies supporting an IND, 21 CFR 58.195 requires raw data and specimens to be retained at least 5 years after the results are submitted to FDA, and if the facility closes, the records transfer to the sponsor's archive [10]. Name the archive location in the contract. Penalty clauses are hard to enforce; milestone payments tied to accepted deliverables work better.

How should I run the relationship week to week?

Appoint one accountable sponsor lead. A Tufts survey of 88 outsourcing professionals, published in 2020, found oversight is generally run by middle managers focused on reactive issues, while executive involvement is minimal and highly variable [11]. In a virtual biotech the executive is the oversight function. I hold a fixed weekly call with a standing agenda: status against plan, deviations, open queries, budget versus forecast, and decisions needed. Every decision goes into a dated log.

The minutes are evidence, not bureaucracy. FDA's compliance program directs inspectors to determine whether sponsor and CRO meetings were held, how often, and for what purpose, and to obtain minutes relevant to any deviation [8]. A survey of 18 German research-based pharmaceutical companies concluded that oversight rests on transparent communication, clear quality expectations, defined accountability, and documented oversight evidence [12].

Agree the escalation path in advance. E6(R3) asks sponsors to escalate issues promptly and, where a service provider's significant noncompliance persists, to consider ending its participation [4]. Under 21 CFR 312.56 the sponsor must monitor all investigations under its IND and, on finding an unreasonable risk, discontinue the affected studies and notify FDA, IRBs, and investigators within 5 working days [13]. You cannot meet that clock if data reaches you a month late.

What does scientific oversight look like in practice?

I do not sign a CRO-drafted protocol without a line-by-line review against the target product profile, and I insist on raw data listings at pre-agreed points, not summary tables. On a GLP toxicology study I oversaw, the draft report read cleanly, but the summary omitted individual dose formulation results. I asked for them. One dose group was outside its acceptance range for part of the dosing period, and the CRO's quality unit had not flagged it. We documented the deviation, assessed the impact, and repeated the analysis before the report was finalized.

FDA's 2013 risk-based monitoring guidance states that sponsors who transfer monitoring to a CRO retain responsibility for oversight, including periodic review of monitoring reports, vendor performance metrics, and documented communication about findings [14]. It also notes that one multicenter trial review found centralized monitoring could have identified more than 90% of on-site findings [14].

What will an FDA inspector ask about my CRO oversight?

FDA's Compliance Program 7348.810, implemented September 15, 2021, governs inspections of sponsors and CROs and directs inspectors to review the sponsor's oversight of outsourced services, especially primary efficacy endpoint or safety data management [8]. They ask whether the sponsor selected the CRO for its ability to comply with regulations, who holds final decision authority for each activity, and whose SOPs were followed [8].

Relationships fail from both sides. On the sponsor side I see unrealistic timelines, late decisions, and scope creep without change orders. On the CRO side I see staff turnover, summary-level reporting, and undisclosed subcontracting, which E6(R3) explicitly brings within the sponsor's oversight duty [4]. Oversight cannot substitute for a vendor's own quality system. If you are redoing their quality control, change vendors.

This article is part of the Product Development Services practice at Hamilton Atlas Group — see the full capability list there.

References

1. Legal Information Institute, Cornell Law School. 21 CFR § 312.3 - Definitions and interpretations. Cornell Law School, 2025.
2. Legal Information Institute, Cornell Law School. 21 CFR § 312.50 - General responsibilities of sponsors. Cornell Law School, 2025.
3. Legal Information Institute, Cornell Law School. 21 CFR § 312.52 - Transfer of obligations to a contract research organization. Cornell Law School, 2025.
4. International Council for Harmonisation. Guideline for Good Clinical Practice E6(R3), Final version, Adopted on 06 January 2025. ICH, 2025.
5. U.S. Food and Drug Administration. E6(R3) Good Clinical Practice (GCP). FDA, 2025.
6. Legal Information Institute, Cornell Law School. 21 CFR § 312.53 - Selecting investigators and monitors. Cornell Law School, 2025.
7. Legal Information Institute, Cornell Law School. 21 CFR § 58.35 - Quality assurance unit. Cornell Law School, 2025.
8. U.S. Food and Drug Administration. Compliance Program 7348.810: Sponsors and Contract Research Organizations. FDA, 2021.
9. U.S. Food and Drug Administration. Instructions for Filling Out Form FDA 1571 Investigational New Drug Application (IND). FDA, 2024.
10. Legal Information Institute, Cornell Law School. 21 CFR § 58.195 - Retention of records. Cornell Law School, 2025.
11. Wilkinson M, Harper B, Peacock J, Morrison R, Getz K. Assessing Outsourcing Oversight Practices and Performance. Therapeutic Innovation & Regulatory Science. 2020;54(1):158-166.
12. Hennig M, Hundt F, Busta S, et al. Current practice and perspectives in CRO oversight based on a survey performed among members of the German Association of Research-Based Pharmaceutical Companies (vfa). GMS German Medical Science. 2017;15:Doc02.
13. Legal Information Institute, Cornell Law School. 21 CFR § 312.56 - Review of ongoing investigations. Cornell Law School, 2025.
14. U.S. Food and Drug Administration. Oversight of Clinical Investigations — A Risk-Based Approach to Monitoring. FDA, 2013.